GRAIL, Inc. (GRAL), the Menlo Park, California-based developer of the Galleri multi-cancer early detection (MCED) blood test, has been one of the most volatile healthcare names of 2026. After more than doubling off its 52-week low near $41, shares closed at $135.46 on October 15, 2026, leaving investors to ask how much of the regulatory optimism is already reflected in the price and whether a move to roughly $165 is realistic.
Because the stock has rallied so sharply, the full analyst range now brackets the market price. Recent actions include TD Cowen raising its target to $180 from $88 (Buy), UBS lifting its target to $175 from $105 (Buy), Guggenheim moving to $155 from $75 (Buy), and Canaccord Genuity raising its target to $150 from $80 (Buy). More cautious firms have also marked up their numbers: Morgan Stanley went to $120 from $60 (Equal-Weight), Goldman Sachs to $120 from $75 (Hold), Baird to $118 (Outperform), Mizuho to $100 (Neutral), and RBC Capital initiated at Sector Perform with an $84 target.
Across these and other valid estimates, the full range spans roughly $74 to $180, and the overall mean of all targets sits near $131 — modestly below the current share price. Under a minimum-distance discipline that requires the target to be at least 10% above the last close, the central target is therefore calculated using only the four targets above $135.46: $180, $175, $155, and $150, which average $165. The spread between the cautious and bullish camps is unusually wide because the debate is not about whether Galleri works, but how quickly — and how profitably — it can be commercialized.
At $135.46, shares are up well over 50% in roughly a month and sit just beneath their 52-week high of $166.48. A move to $165 implies roughly 22% upside, which is substantial given the stock has already absorbed a wave of positive headlines tied to Galleri's FDA advisory committee process. The path to $165 would likely require a favorable FDA decision, an acceleration in Galleri test volumes, and analyst estimates continuing to rise rather than merely holding.
The core bull case rests on Galleri, a screening test designed to detect multiple cancers from a single blood draw. FDA briefing documents released in late September showed no major safety concerns, and the advisory committee vote — described by Canaccord as "better than expected" — removed a key overhang. GRAIL is also commercializing through large-scale programs such as the NHS Galleri trial and PATHFINDER 2, and new clinical data was scheduled for the EDCC and ESMO 2026 medical meetings. Revenue is growing from a small base — roughly $44.7 million in the quarter ended June 30, 2026, up from about $35.5 million a year earlier — and the addressable market for early cancer detection is large.
The company is not yet profitable. Trailing twelve-month net income available to common shareholders was deeply negative, and EPS (earnings per share) over the trailing twelve months was around -$9.36. GRAIL trades at a premium valuation on a price-to-sales basis, well above the broader diagnostics group, which leaves little room for disappointment. The cautious $74 to $120 targets reflect concerns about the pace of physician adoption, reimbursement coverage, competition in the liquid-biopsy space, and the risk that a long-awaited approval triggers profit-taking. The FDA panel vote itself was characterized by BTIG as "closer than we expected," a reminder that regulatory outcomes remain uncertain.
The $165 central target sits almost exactly at the 52-week high of $166.48, making that level a clear technical ceiling the stock has yet to decisively clear. Below the market, the prior consolidation zone near $110 to $120 — where shares traded after a roughly 37% single-session jump — and the round-number $100 level form potential support. The 52-week range from $41.50 to $166.48 illustrates just how far sentiment has traveled in a short period.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary widely given the binary nature of the regulatory catalysts. The most consequential near-term items are the FDA's approval decision on Galleri, third-quarter results expected around November 11, 2026, subsequent analyst target revisions, and any data presented at major oncology meetings. Reimbursement decisions and volume trends in Galleri testing will matter as much as the headline approval itself.
For traders navigating a fast-moving name like GRAIL, AI Daily Buy/Sell Signals from Tickeron offers a data-driven way to keep pace. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help active investors discover opportunities, monitor existing positions, and spot emerging trend changes more efficiently than manual screening alone. As GRAIL approaches a pivotal regulatory decision, adding an AI signal layer can help filter short-term noise from durable trend shifts.
Can GRAIL reach $165? The target is not a guaranteed outcome but the average of four bullish analyst price targets that sit above the current share price, each tied to a constructive view of Galleri's commercial runway. It implies about 22% upside and sits just below the stock's 52-week high, meaning the market has already priced in much of the optimism. Strong demand fundamentals and a favorable regulatory trajectory support the bull case, while persistent losses, a rich valuation, wide analyst disagreement, and the risk of a post-approval pullback are the principal obstacles. The FDA decision and the pace of Galleri adoption — not the headline target itself — will determine whether the move materializes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GRAL has been loosely correlated with PSNL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GRAL jumps, then PSNL could also see price increases.
| Ticker / NAME | Correlation To GRAL | 1D Price Change % | ||
|---|---|---|---|---|
| GRAL | 100% | +3.91% | ||
| PSNL - GRAL | 51% Loosely correlated | +1.47% | ||
| ADPT - GRAL | 47% Loosely correlated | -0.29% | ||
| TWST - GRAL | 44% Loosely correlated | +5.29% | ||
| GH - GRAL | 44% Loosely correlated | -0.45% | ||
| NTRA - GRAL | 41% Loosely correlated | +1.52% | ||
More | ||||
| Ticker / NAME | Correlation To GRAL | 1D Price Change % |
|---|---|---|
| GRAL | 100% | +3.91% |
| Medical Specialties category (43 stocks) | 28% Poorly correlated | +0.06% |
| Medical Specialties category (43 stocks) | 28% Poorly correlated | +0.06% |